AZURRX BIOPHARM (NASDAQ:AZRX) major shareholder Pelican Partners Llc sold 160,000 shares of the business’s stock in a transaction on Friday, June 30th. The stock was sold at an average price of $3.19, for a total transaction of $510,400.00. Following the transaction, the insider now directly owns 1,787,796 shares of the company’s stock, valued at approximately $5,703,069.24. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
AZURRX BIOPHARM (AZRX) opened at 4.28 on Friday. AZURRX BIOPHARM has a 12-month low of $3.07 and a 12-month high of $5.60. The company’s market cap is $41.22 million. The stock’s 50 day moving average is $3.80 and its 200 day moving average is $3.92.
TRADEMARK VIOLATION NOTICE: “AZURRX BIOPHARM (NASDAQ:AZRX) Major Shareholder Sells $510,400.00 in Stock” was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.chaffeybreeze.com/2017/07/29/pelican-partners-llc-sells-160000-shares-of-azurrx-biopharm-nasdaqazrx-stock-updated-updated-updated.html.
Separately, HC Wainwright began coverage on shares of AZURRX BIOPHARM in a report on Monday, July 24th. They set a “buy” rating and a $8.00 price objective on the stock.
AZURRX BIOPHARM Company Profile
AzurRx BioPharma, Inc is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101.
Receive News & Ratings for AZURRX BIOPHARM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AZURRX BIOPHARM and related companies with MarketBeat.com's FREE daily email newsletter.